Zifanocycline (KBP-7072), a third-generation semisynthetic aminomethylcycline antibiotic, inhibits bacterial ribosome function, displaying broad-spectrum antibacterial activity in vitro against both Gram-positive and Gram-negative bacteria, notably multidrug-resistant strains. It is formulated for oral and injectable use, targeting research on acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, and complicated intra-abdominal infections [1] [2].